uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged > 80 Years: An Interim Analysis of the EXELS Study
Show others and affiliations
2013 (English)In: Clinical drug investigation, ISSN 1173-2563, Vol. 33, no 1, 55-63 p.Article in journal (Refereed) Published
Abstract [en]

Background The median age of patients diagnosed with essential thrombocythaemia (ET) is 65-70 years but the management of very elderly patients (aged >80 years) with ET has not been well characterized. Objective This study aimed to document the treatment patterns of very elderly patients with ET in a multinational, real-world setting. Study Design EXELS (Evaluation of Xagrid Efficacy and Long-term Safety) is a phase IV observational study, designed to monitor the efficacy and safety of cytoreductive therapies in clinical practice. In total, 3,598 high-risk patients with ET were recruited from May 2005 to April 2009, in 13 European countries. Data were collected at registration and every 6 months thereafter for 5 years. This analysis was performed on a data-cut taken approximately 2 years after the last patient was registered. Patients In total, 395 patients aged >80 years at registration into EXELS were included in the analysis; of these, 42.2 % had experienced a previous thrombohaemorrhagic event. Results At registration, the most frequently prescribed cytoreductive therapy for patients aged >80 years was hydroxycarbamide (HC), which accounted for 82.8 % of patients whereas anagrelide use was less frequent (8.6 %). Very elderly patients were more likely to be switched from anagrelide than from HC (47.1 vs. 17.4 %; 95 % confidence interval for difference in proportion 12.4-46.9; Chi-squared test p < 0.001). Median platelet count during treatment was similar to 430 x 10(9)/L. In patients aged >80 years, the main reason for switch was intolerance/side effects (34.1 %); 0/16 patients reported treatment with anagrelide was non-efficacious compared with 8/57 (14 %) patients receiving HC, and 7/16 (43.8 %) anagrelide patients switched because of intolerance versus 18/57 (31.6 %) patients receiving HC. At least one predefined clinical event (PDE) was experienced by 27.3 % of patients aged >80 years. The most common PDEs reported in the very elderly age group were death (non-PDE related; 11.1 %), other cardiovascular symptoms (5.8 %), haematological transformation (3.8 %), congestive heart failure (3.3 %), myocardial infarction and angina (2.8 %), and thromboembolic events (6.3 %). Conclusion Well-tolerated and effective cytoreductive therapy has been achieved in patients aged >80 years by following individual treatment modalities that appear in agreement with the recent European LeukemiaNet (ELN) guidelines. Clinical Trial Registration Registered as ClinicalTrials.gov identifier NCT00567502; Protocol No: SPD422-401.

Place, publisher, year, edition, pages
2013. Vol. 33, no 1, 55-63 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-198640DOI: 10.1007/s40261-012-0042-0ISI: 000316411300006OAI: oai:DiVA.org:uu-198640DiVA: diva2:617121
Available from: 2013-04-22 Created: 2013-04-22 Last updated: 2013-04-22Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Birgegård, Gunnar
By organisation
In the same journal
Clinical drug investigation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 192 hits
ReferencesLink to record
Permanent link

Direct link